Takeda
Global biopharmaceutical firm; R&D-driven NMEs
Manager – Access Data Products & AI Analytics
About the job
- Bachelor’s degree in Statistics, Business, Information Systems, Computer Science, Engineering, Analytics, Life Sciences, or a related field required.
- 7+ years of experience in data analytics, business intelligence, reporting, data product delivery, data operations, commercial analytics, or business analysis.
- Experience leading small teams, delivery workstreams, analysts, QA resources, or reporting specialists.
- Experience translating business needs into requirements, user stories, data definitions, source-to-target mappings, testing scenarios, and validation plans.
- Strong Python and SQL skills required.
- Hands-on experience with data analysis, data profiling, reconciliation, validation, QA, and root-cause investigation required.
- Working knowledge of data modeling, metadata, lineage, source-to-target mapping, data governance, MDM, and controlled data consumption.
- Understanding of data privacy, compliance, and appropriate use considerations for healthcare and commercial pharma data.
- Strong analytical problem-solving skills and ability to connect data findings to business impact.
- Clear communication skills, with the ability to explain data issues, requirements, and analytical findings to both business and technical audiences.
- Strong execution discipline, attention to detail, and ownership of quality, timelines, and documentation.
- Ability to work effectively across time zones with U.S. business partners, GCC teams, DD&T, vendors, and analytics stakeholders.
- Curiosity and willingness to build deeper Access domain knowledge across payer, reimbursement, affordability, hub, specialty pharmacy, formulary, and patient services topics.
- Ability to manage ambiguity, prioritize competing work, and escalate issues with clear options and recommendations.
- Willingness to challenge unclear requirements, inconsistent definitions, weak data controls, or outputs that are not fit for business use.
- Ability to coach analysts and help build stronger technical, analytical, domain, and AI-enabled analytics capabilities within the GCC team.
- Support delivery of Access data products across payer, plan, formulary, coverage, reimbursement, affordability, patient services, hub, specialty pharmacy, prior authorization, claims, and access performance domains.
- Translate business questions and stakeholder needs into clear requirements, user stories, acceptance criteria, source-to-target mappings, data definitions, and validation scenarios.
- Partner with the Senior Manager, U.S. Access Data Products Director, DD&T, data engineering teams, analytics teams, and reporting teams to ensure assigned data products are delivered with quality and business relevance.
- Maintain product backlogs, delivery trackers, issue logs, release notes, documentation, and validation evidence for assigned Access data products.
- Support standardization and reuse across Access data products, helping reduce fragmented, manual, or one-off datasets.
- Perform hands-on data analysis to profile data, validate logic, investigate discrepancies, and confirm data readiness for analytics and reporting use cases.
- Use SQL and modern data platforms, especially Databricks or similar environments, to support data exploration, transformation validation, reconciliation, and analytics-ready dataset preparation.
- Partner with data engineers and platform teams to review data models, transformation logic, refresh processes, and consumption layers.
- Support creation and validation of semantic layers, curated data marts, reusable business logic, and certified metrics for Access analytics and reporting.
- Identify opportunities to automate recurring data checks, validation routines, reporting support, and data quality monitoring.
- Support AI/BI and GenAI-enabled analytics use cases that improve data discovery, self-service reporting, data quality investigation, documentation, and insight generation.
- Assist in developing and validating conversational analytics capabilities, including natural language querying, governed semantic layers, reusable analytical prompts, and business-friendly data exploration experiences.
- Bring practical understanding of LLMs, small language models, prompt engineering, retrieval-augmented generation, and responsible AI concepts as they apply to commercial pharma data and analytics.
- Partner with the Senior Manager and platform teams to test AI-enabled workflows and ensure outputs are accurate, explainable, governed, and appropriate for business use.
- Help business users adopt AI-enabled analytics capabilities by supporting training materials, FAQs, examples, documentation, and issue resolution.
- Perform hands-on data quality checks, including completeness, timeliness, accuracy, consistency, business rule adherence, and reconciliation against source or control totals.
- Create and maintain validation scripts, QA checklists, exception reports, control files, and issue-resolution documentation.
- Investigate data discrepancies, identify root causes, coordinate remediation with technical teams, and communicate business impacts clearly.
- Support data quality KPIs and monitoring routines for assigned Access data products.
- Ensure business rules, metric definitions, lineage, source-to-target mappings, transformation logic, assumptions, limitations, and known caveats are documented and maintained.
- Follow Takeda’s data governance, privacy, metadata, lineage, and appropriate-use standards for healthcare and commercial pharma data.
- Support trusted home office, market access, patient services, and franchise-level reporting by ensuring assigned Access data products are accurate, timely, and decision-ready.
- Partner with A&I and reporting teams to validate dashboards, scorecards, metrics, extracts, and analytical outputs that rely on Access data products.
- Support analytics use cases related to payer engagement, coverage and formulary performance, affordability, reimbursement, prior authorization, hub operations, specialty pharmacy performance, patient journey, and access performance measurement.
- Help identify opportunities to improve time-to-insight through reusable data logic, better documentation, improved data models, automated checks, and simplified data consumption.
- Support adoption of centralized Access data products and help transition users away from non-standard or manual reporting processes where appropriate.
- Work closely with U.S. and GCC stakeholders across PAMA, A&I, Commercial Operations, DD&T, franchise analytics teams, and vendors to clarify requirements, resolve issues, and support delivery.
- Collaborate with external data and analytics partners as needed, including vendors and consulting partners supporting Access data, commercial pharma analytics, data engineering, and AI-enabled analytics.
- Bring working knowledge of commercial pharma data vendor ecosystems, including IQVIA, Axtria, ZS, specialty pharmacy data partners, hub vendors, claims vendors, payer/formulary data providers, and related partners.
- Communicate status, risks, dependencies, issues, and decisions clearly to the Senior Manager and relevant stakeholders.
- Manage and coach a small team of analysts, QA resources, or reporting specialists supporting assigned Access data product workstreams.
- Experience with Databricks, SQL, BI tools, AI-enabled analytics capabilities, conversational analytics, GenAI, large language models, small language models, and natural language data exploration is preferred.
- Prior experience with ZS, Axtria, IQVIA, or similar life sciences analytics, data strategy, or consulting organizations is preferred.
- Experience supporting U.S. commercial pharma stakeholders across Market Access, Patient Services, Commercial Operations, Analytics & Insights, or brand/franchise teams is preferred.
- Experience with commercial pharma data sources such as claims, specialty pharmacy, hub, payer, plan, formulary, IQVIA, LAAD, LAAD Plus, DDD, 852/867, patient services, market access, or affordability data is preferred.
- Experience leading small teams, delivery workstreams, analysts, QA resources, or reporting specialists is desirable.
- Exposure to Databricks AI/BI capabilities, Genie or Gene-style conversational analytics, natural language querying, or AI-assisted data exploration is preferred.
- Basic understanding of LLMs, small language models, prompt engineering, retrieval-augmented generation, conversational analytics, and responsible AI concepts is preferred.
- Experience using AI or GenAI tools to improve analytics workflows, reporting, documentation, data quality, or user self-service is preferred.
- Leadership behaviors and ability to coach analysts and build AI-enabled analytics capabilities within GCC team is preferred.
About the company
Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.
Company Size
10,001+
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1781
Get referred to Takeda
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 2026 FDA approval for MIMRYLO unlocks near-term U.S. oncology revenue.
- Takeda expects ORZEYFUL U.S. launch by November 2026, pending DEA scheduling.
- Q1 FY2026 new launches grew 22.6%, offsetting mature-brand declines and supporting guidance.
What critics are saying
- May 18, 2026 AMITIZA verdict exposed Takeda to $2.6 billion treble-damage risk.
- Takeda plans 4,500 FY2026 cuts, signaling launch execution pressure and organizational churn.
- Patent erosion crushed VYVANSE sales 60.7% at constant currency in Q1 FY2026.
What makes Takeda unique
- ORZEYFUL became the first orexin agonist approved for narcolepsy type 1 in 2026.
- MIMRYLO offers first-in-class hepcidin mimetic therapy for polycythemia vera after FDA approval.
- Takeda pairs global scale with Japanese discovery, including Shonan-led neurology innovation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Wellness Program
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Trialbee, a patient recruitment platform provider, will present at DPHARM 2026 in Boston on 15-16 September. The Swedish-American company will unveil AI-powered patient screening in its Honey Platform, enabling conversational AI chatbots to conduct initial candidate assessments whilst giving patients the option to speak with recruitment specialists. Trialbee will present jointly with pharmaceutical company Takeda on integrating their respective platforms to build research-ready patient communities that extend beyond single trials. The company will also participate in a panel discussing AI applications at clinical trial sites. The Honey Platform has added several AI features this year, including candidate summaries, duplicate detection, and recruitment data analysis. Trialbee supports over 6,000 research sites across 50 countries and reports a 91% repeat business rate with biopharmaceutical companies.
Onco360, a US independent speciality pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO (rusfertide). The treatment is indicated for erythrocytosis in adults with polycythemia vera. MIMRYLO is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. This inhibition reduces iron availability for red blood cell production, resulting in lower hematocrit levels. The drug's approval was based on the phase 3 VERIFY study, a global, randomised, open-label clinical trial. The primary endpoint measured the proportion of patients achieving response during weeks 20-32, defined as the absence of phlebotomy eligibility. The most common adverse reactions were injection site reactions at 56% and anaemia at 16%.
The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.
Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.
Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.